JAN 09, 2018 06:17 AM PST

Something Else for Beta Blockers to Do: Treat Melanoma

WRITTEN BY: Kara Marker

A drug used to lower blood pressure and prevent heart attacks could also be used to treat melanoma. From Penn State, researchers are studying how a specific type of beta blocker - widely available and approved by the FDA - can improve the effectiveness of cancer immunotherapy for melanoma patients whose cancer has spread to different tissues in the body.

Credit: Penn State / © iStock Photo / digicomphoto

Beta blockers reduce blood pressure by opening up blood vessels to improve blood flow and prevent heart attacks by inhibiting the effects of epinephrine, a hormone also called adrenaline. Pan beta blockers are commonly known to be safe, which means that they could be more quickly applied to melanoma patients than a newly developed drug. In theory, beta blockers are able to lower stress to empower the immune system to fight cancer on its own.

"Most patients are either prescribed beta-1 selective blockers or are not taking beta blockers at all,” explained Dr. Todd Schell. “This means there's a large population of patients who may be eligible to take pan beta blockers while being treated with immunotherapy.”

Metastatic melanoma patients receiving immunotherapy may have the best chance at living longer, although even with the treatment the response rates are low - less than 35 percent. “How can we make these treatments better?” asked Penn State’s Dr. Joseph Drabick.

"Beta blockers slow your heart rhythm, but they can also affect immune cells and improve immune function," Schell said. "We wanted to see if there would be a correlation between the beta blockers patients were taking for another condition and their response to immunotherapy.”

The new Penn State study involved giving beta blockers to melanoma patients receiving cancer immunotherapy as opposed to just immunotherapy. Of 195 metastatic melanoma patients being treated with immunotherapy, 62 were also taking beta blockers. Schell, Drabick, and the other researchers compared survival between patients taking two different kinds of beta blockers, beta 1-selective and pan beta blockers, and patients taking no beta blockers at all.

The results showed that patients taking pan beta blockers were significantly more likely to survive (70 percent alive after five years of immunotherapy) than patients taking beta 1-selective beta blockers or no beta blockers at all (25 percent). Researchers completed virtually the same study again, this time in mice with melanoma. Like the human trial, the mice were receiving immunotherapy with or without additional treatment of pan beta blockers. Immunotherapy plus pan beta blockers delayed tumor growth and increased survival.

“We saw that for patients taking pan beta blockers, there was a dramatic improvement in survival, and we were able to duplicate these findings in mice and see the exact same phenomenon,” Drabick explained.

Going forward, the Penn State researchers will continue their study on using beta blockers to improve immunotherapy to potentially treat a variety of cancers.

The present study was published in the journal OncoImmunology.

Sources: MayoClinic, Penn State

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
NOV 21, 2019
Health & Medicine
NOV 21, 2019
Bartonella henselae Infection Implicated in Pediatric Acute-Onset Neuropsychiatric Syndrome
Pediatric acute-onset neuropsychiatric syndrome (PANS) is a term used to describe every cause of acute-onset of obsessive-compulsive disorder including str...
NOV 21, 2019
Cancer
NOV 21, 2019
Widely Prescribed Breast Cancer Medication Promotes Metastasis
The primary goals of metastatic breast cancer treatment are to ensure that the patient has the longest survival possible while experiencing the highes...
NOV 21, 2019
Health & Medicine
NOV 21, 2019
Siblings lead Researchers to Discover New Immunodeficiency Disease
An infant was suffering from inflammatory bowel disease, eczema, food allergies, lung disease, and persistent cytomegalovirus (CMV) infection. His older si...
NOV 21, 2019
Health & Medicine
NOV 21, 2019
Why does the flu virus thrive during winter?
If you’re one of the nearly 7 million people who suffered from influenza last season, you might be curious why the virus hits so much during winter m...
NOV 21, 2019
Immunology
NOV 21, 2019
Are Bacteria Fighting Cancer For Us?
Scientists at the Sanford Burnham Prebys Medical Discovery Institute found that the RNF5 enzyme, produced by a gene in gut microbes affects tumor growth.&n...
NOV 21, 2019
Immunology
NOV 21, 2019
Allergy Shots May Work for Kids with Pollen Food Allergy Syndrome
It’s not common for young children to develop pollen food allergy syndrome (PFAS), but for those that do, there’s not too much parents can do o...
Loading Comments...